Bioporto A/S logo

BIOPOR - Bioporto A/S News Story

DKK5.21 -0.2  -3.0%

Last Trade - 11:03am

Sector
Industrials
Size
Small Cap
Market Cap £167.6m
Enterprise Value £156.3m
Revenue £2.71m
Position in Universe 759th / 1830

BRIEF-Bioporto A/S - Q3 EBIT Loss Dkk 17.7 Million

Wed 18th November, 2020 8:12am
Nov 18 (Reuters) - Bioporto A/S  BIOPOR.CO :
    * REG-BIOPORTO ANNOUNCES Q3 2020 REPORT
    * REG-BIOPORTO ANNOUNCES Q3 2020 REPORT
    * BIOPORTO A/S - GUIDANCE FOR 2020 MAINTAINED
    * BIOPORTO A/S - PROVIDED CLINICAL STUDY IS COMPLETED ACCORDING TO PLAN AND EUA IS GRANTED,
CO
EXPECTS TO BE ABLE TO INITIATE COMMERCIALIZATION IN BEGINNING OF 2021
    * BIOPORTO A/S - PRODUCT SALES OF NGAL TEST GREW BY 58% YEAR-TO-DATE
    * BIOPORTO A/S - ANALYTICAL STUDIES FOR NGAL TEST™ APPLICATION ON TRACK, BUT COVID-19 SLOWS
CLINICAL ENROLLMENT
    * BIOPORTO A/S - Q3 REVENUE DKK 4.7  MILLION VERSUS DKK 6.6 MILLION YEAR AGO
    * BIOPORTO A/S - Q3 EBIT LOSS DKK 17.7 MILLION VERSUS LOSS DKK 24.0 MILLION YEAR AGO

Source text for Eikon:  ID:nGNE1CQ3sM 
Further company coverage:  BIOPOR.CO 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.